source
- Valneva's Shigella vaccine cuts infection rates in phase 2 trialValneva reported that its Shigella vaccine reduced the number of intestinal infections in a phase 2 controlled human infection model study conducted in the United States. The trial enrolled 120 he…
- Kyorin signs $140M deal for Japan rights to Edesa's ARDS antibodyKyorin Pharmaceutical will pay $12 million up front and up to $134 million in milestones, plus royalties, for exclusive Japan rights to Edesa Biotech’s anti‑TLR4 antibody, paridiprubart, intended f…